Sanofi's rash of dealmaking has continued with a $ ... are spearheaded by its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales, and the drugmaker ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Seek emergency medical care if you have a high fever, difficulty breathing, nausea or dizziness, or the rash is spreading rapidly. A rash is an area of skin that may be inflamed, irritated ...

A sun rash — known medically as a polymorphic light eruption — is a skin reaction due to sun exposure. It may cause irritation but does not usually result in serious complications. It ...

There are many potential reasons babies develop rashes. While rashes on babies are common, and most are not a cause for alarm, they can be uncomfortable and cause irritation. Often, there may be ...

Heat rash is a skin condition that develops in hot, humid environments. It causes small discolored or fluid-filled blisters to develop in the folds of your skin or areas where clothing rubs the skin.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

We would have people coming into us because they saw a video on TikTok that if they put shampoo on their face it would clear their acne, but they break out in a big rash Dr Grimes said the problem ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...